RxDoctor Payments Data

Rana Marzouq, MD

Internal Medicine · Jersey City, NJNPI 1659832541

Payments from drug & device makers

$161in general payments, 2019–2025

Across 8 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$50
  • Astellas Pharma US Inc$30
  • AstraZeneca$21
  • Shield Therapeutics Inc$17
  • AbbVie$15
  • GSK$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$161 in reported general payments places this provider in the 35th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$295,596
Medicare patients
656
Services billed
4,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$213,602
OzempicSemaglutide181$187,618
JardianceEmpagliflozin86$84,104
JanuviaSitagliptin Phosphate66$83,015
MounjaroTirzepatide49$51,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$44,442
FarxigaDapagliflozin Propanediol50$41,300
TrulicityDulaglutide22$25,993
MyrbetriqMirabegron34$24,442
EntrestoSacubitril/Valsartan15$22,315
RybelsusSemaglutide18$21,394
JanumetSitagliptin Phos/Metformin Hcl11$18,530
Praluent PenAlirocumab18$16,682
LinzessLinaclotide23$15,539
Repatha SureclickEvolocumab18$14,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$209,012199 claims
Lilly USA, LLCMounjaro, Trulicity$50$77,44171 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$14$67,01091 claims
AstraZenecaFarxiga, Symbicort$21$46,58967 claims
Astellas Pharma US IncMyrbetriq, Veozah$30$30,77846 claims
AbbVieLinzess, Creon$15$24,32034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →